万达制药周三表示，其用于社交焦虑障碍的实验药物未能达到晚期研究的主要目标，促使公司在进一步分析数据之前暂停该项目。该生物制药公司股票在延长交易时段下跌约17%。
公司表示，该研究未显示药物VQW-765在公开演讲压力测试中相比安慰剂能减轻焦虑，并补充称，该药物在更广泛的研究人群中也未达到一个关键的次要目标。
Vanda Pharmaceuticals said on Wednesday its experimental drug for social anxiety disorder failed the main goal of a late-stage study, prompting the company to put the program on hold pending further analysis of the data.
该晚期试验在美国约30个地点招募了546名社交焦虑障碍成人。
Shares of the biopharmaceutical company were down about 17% in extended trading.
该研究旨在验证早期中期试验的结果，而早期试验曾提示该药物可能减轻焦虑症状，万达制药称。晚期试验结果未能证实早期发现，公司称。
万达制药表示，VQW-765的开发项目目前处于暂停状态，而公司正在审查完整数据集。该药物安全且耐受性良好，这与之前的研究结果一致，公司称。
The study did not show that the drug, VQW-765, reduced anxiety compared to placebo during a public-speaking stress test, the company said, adding that it also missed a key secondary goal in the broader study population The late-stage trial enrolled 546 adults with social anxiety disorder at about 30 sites across the United States The study was designed to confirm findings from an earlier mid-stage trial, which had suggested the drug could reduce anxiety symptoms, Vanda said The late-stage results did not confirm the earlier findings, it said The VQW-765 development program, Vanda said, is on hold while it reviews the full dataset The drug was safe and well tolerated, consistent with prior studies, it said